News | February 09, 2009

Paclitaxel Stents Shown to be Effective in Treating Bypass Vein Grafts

February 9, 2009 - Implantation of drug-eluting stents to treat degenerative in aortocoronary saphenous vein graft (SVG) lesions is safe, according to a study published in the Jan. 15 issue of the American Journal of Cardiology (Vol. 103, issue 2, Pages 199-202).

The Paclitaxel-Eluting Stent Long-Term Outcomes in Percutaneous Saphenous Vein Graft Interventions (PELOPS) Study by researchers at the Cardiac Medical Unit of Grantham Hospital and the Department of Medicine at Queen Mary Hospital, both in Hong Kong, said paclitaxel-eluting stents in SVGs showed an association with low late loss, angiographic restenosis, and MACE at one-year follow-up.

Sixty-eight consecutive patients with 90 nonoccluded SVG lesions were treated with a Taxus stents ranging in size from 2.25 to 4.5 mm. Angiographic follow-up was performed on 63 patients (93 percent) and 83 lesions (92 percent) at 12 months. Researchers said major adverse cardiac event (MACE) was recorded in all patients at one year. The mean age of patients was 71 with predominance of men (75 percent). Glycoprotein IIb/ IIIa inhibitors were given in 21 patients (31 percent). Embolic protection devices were used in 54 lesions (60 percent). On average, patients received 1.4 stents per lesion with a stent size of 3.4 ± 0.6 mm and a length of 35.8 ± 27 mm.

Angiographic follow-up revealed a late loss of 0.36 ± 0.66 mm with an in-segment binary restenosis rate of 7 percent. The in-hospital MACE was 7 percent, which was solely contributed by 5 patients with postprocedure non–Q myocardial infarction. The one-year MACE was 15 percent, accounted by one noncardiac death and nine patients with target vessel revascularization. Peripheral vascular disease and the use of glycoprotein IIb/ IIIa inhibitors were the independent predictors of MACE at one year, the researchers said.

For more information: www.ajconline.org

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init